Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Exact Sciences Corp (NASDAQ: EXAS) closed at $56.11 down -2.21% from its previous closing price of $57.38. In other words, the price has decreased by -$2.21 from its previous closing price. On the day, 2.06 million shares were traded. EXAS stock price reached its highest trading level at $57.44 during the session, while it also had its lowest trading level at $55.65.
Ratios:
For a deeper understanding of Exact Sciences Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.17 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 105.50. For the most recent quarter (mrq), Quick Ratio is recorded 1.93 and its Current Ratio is at 2.12. In the meantime, Its Debt-to-Equity ratio is 0.87 whereas as Long-Term Debt/Eq ratio is at 0.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on August 28, 2024, initiated with a Overweight rating and assigned the stock a target price of $75.
On June 27, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $70.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 13 ’24 when Conroy Kevin T bought 19,500 shares for $51.35 per share. The transaction valued at 1,001,325 led to the insider holds 1,074,191 shares of the business.
Baranick Brian sold 929 shares of EXAS for $65,030 on Oct 08 ’24. The EVP, GM, Precision Oncology now owns 12,758 shares after completing the transaction at $70.00 per share. On Oct 08 ’24, another insider, Baranick Brian, who serves as the Officer of the company, bought 929 shares for $70.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 10384614400 and an Enterprise Value of 12144592896. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.86 while its Price-to-Book (P/B) ratio in mrq is 3.23. Its current Enterprise Value per Revenue stands at 4.511 whereas that against EBITDA is -1071.235.
Stock Price History:
Over the past 52 weeks, EXAS has reached a high of $79.62, while it has fallen to a 52-week low of $40.62. The 50-Day Moving Average of the stock is -9.58%, while the 200-Day Moving Average is calculated to be -3.67%.
Shares Statistics:
For the past three months, EXAS has traded an average of 2.48M shares per day and 1876580 over the past ten days. A total of 185.05M shares are outstanding, with a floating share count of 182.38M. Insiders hold about 1.46% of the company’s shares, while institutions hold 99.85% stake in the company. Shares short for EXAS as of 1732838400 were 11828001 with a Short Ratio of 4.78, compared to 1730332800 on 14059827. Therefore, it implies a Short% of Shares Outstanding of 11828001 and a Short% of Float of 6.45.
